CNO Q4 2025 Earnings Call Summary

CNO Financial Group Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Operating Earnings per Share: Increased by 11% to $4.40, with full-year operating earnings per diluted share at $4.02, exceeding guidance.
Operating Return on Equity: Improved to 11.4%, up from 10% in 2024, on track to reach a target of 12% by 2027.
Total Capital Returned to Shareholders: $386 million, an 11% increase from 2024.
Book Value per Share: Excluding AOCI, was $38.81, reflecting a 7% compound annual growth rate over three years.
Expense Ratio: Improved to 18.9%, better than the low end of guidance.
Net Investment Income: Continued growth for nine consecutive quarters, supported by disciplined portfolio management.

2. Strategic Updates and Business Highlights

Sales Growth: Achieved 14 consecutive quarters of sales growth, with record total new annualized premium (NAP) up 15% for the year.
Consumer Division: Strong performance with life NAP up 10% and total health NAP up 22%. Medicare Supplement NAP surged 49% for the year.
Worksite Division: Best production year ever, with insurance sales up 15% and record life insurance sales up 36%.
Agent Productivity: Continued growth in producing agent count for 12 consecutive quarters, with a focus on enhancing agent productivity.

3. Forward Guidance and Outlook

2026 Guidance: Operating earnings per share expected between $4.25 and $4.45, an 8% increase at the midpoint from 2025.
Expense Ratio: Projected to be in the range of 18.8% to 19.2%.
Free Cash Flow: Anticipated between $200 million and $250 million, supporting capital deployment and strategic investments.
Tech Modernization Initiative: Ongoing investment of approximately $170 million over three years, with $75 million expected in 2026.

4. Bad News, Challenges, or Points of Concern

Economic Headwinds: Concerns about potential impacts from layoffs and a challenging macroeconomic environment, which may affect discretionary purchases, particularly in annuities and life insurance.
Medicare Advantage Market: Anticipated decline in Medicare Advantage sales due to market pressures, with a strategic shift towards Medicare Supplement products.
Visibility Issues: Management expressed uncertainty regarding future economic conditions, citing a lack of visibility in the current environment.

5. Notable Q&A Insights

Earnings Emergence: Paul McDonough indicated that earnings from strong sales may take time to fully materialize, depending on product duration.
Agent Count Growth: Gary Bhojwani confirmed expectations for continued growth in producing agent count, emphasizing productivity over sheer numbers.
Investment Strategy: Discussion on the cautious approach to investment allocations, particularly regarding software and alternatives, with a focus on maintaining quality and risk management.
Medicare Dynamics: Gary highlighted the preference for Medicare Supplement products due to better control and higher net worth consumers, despite challenges in the Medicare Advantage segment.

Overall, CNO Financial Group reported strong financial performance in 2025, with significant growth in sales and profitability, while also navigating potential economic challenges and shifting market dynamics.

CNO — CNO Financial Group, Inc.